Marshall Wace, LLP Biomarin Pharmaceutical Inc Transaction History

Marshall Wace, LLP

$77.3 Billion
Q3 2024

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$74.43 - $92.22 $2.7 Million - $3.35 Million	-36,331 Reduced 45.95%	42,738 $3.52 Million
Q1 2024 May 15, 2024	SELL	$83.81 - $99.0 $29.5 Million - $34.9 Million	-352,274 Reduced 81.67%	79,069 $6.91 Million
Q4 2023 Feb 14, 2024	BUY	$76.22 - $98.51 $17 Million - $22 Million	223,656 Added 107.69%	431,343 $41.6 Million
Q3 2023 Nov 14, 2023	SELL	$85.07 - $94.48 $649,509 - $721,354	-7,635 Reduced 3.55%	207,687 $18.4 Million
Q2 2023 Aug 14, 2023	BUY	$86.68 - $100.3 $17.4 Million - $20.1 Million	200,309 Added 1334.24%	215,322 $18.7 Million
Q1 2023 May 15, 2023	SELL	$87.74 - $117.27 $51.4 Million - $68.6 Million	-585,259 Reduced 97.5%	15,013 $1.46 Million
Q4 2022 Feb 14, 2023	BUY	$80.93 - $108.63 $11.3 Million - $15.1 Million	139,313 Added 30.22%	600,272 $62.1 Million
Q3 2022 Nov 14, 2022	SELL	$82.16 - $96.94 $10.5 Million - $12.4 Million	-127,659 Reduced 21.69%	460,959 $39.1 Million
Q2 2022 Aug 15, 2022	BUY	$71.48 - $86.85 $15.9 Million - $19.3 Million	222,438 Added 60.75%	588,618 $48.8 Million
Q1 2022 May 16, 2022	SELL	$74.28 - $92.69 $19.6 Million - $24.4 Million	-263,254 Reduced 41.82%	366,180 $28.2 Million
Q4 2021 Feb 14, 2022	BUY	$71.72 - $91.47 $21 Million - $26.8 Million	293,449 Added 87.34%	629,434 $55.6 Million
Q3 2021 Nov 15, 2021	BUY	$74.77 - $85.47 $22.1 Million - $25.2 Million	295,034 Added 720.46%	335,985 $26 Million
Q2 2021 Aug 13, 2021	BUY	$75.51 - $84.79 $3.09 Million - $3.47 Million	40,951 New	40,951 $3.42 Million
Q1 2021 May 17, 2021	SELL	$74.73 - $90.69 $4.81 Million - $5.84 Million	-64,396 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$72.61 - $90.2 $16.8 Million - $20.8 Million	-231,129 Reduced 78.21%	64,396 $5.65 Million
Q3 2020 Nov 16, 2020	BUY	$71.87 - $131.03 $15.5 Million - $28.2 Million	215,264 Added 268.2%	295,525 $22.5 Million
Q2 2020 Aug 13, 2020	BUY	$79.55 - $124.22 $5.49 Million - $8.57 Million	69,015 Added 613.68%	80,261 $9.9 Million
Q1 2020 May 15, 2020	SELL	$71.37 - $96.85 $19.2 Million - $26.1 Million	-269,525 Reduced 95.99%	11,246 $951,000
Q4 2019 Feb 14, 2020	BUY	$64.27 - $86.37 $16.4 Million - $22 Million	254,681 Added 976.16%	280,771 $23.7 Million
Q3 2019 Nov 14, 2019	SELL	$67.4 - $85.11 $17.3 Million - $21.8 Million	-256,022 Reduced 90.75%	26,090 $1.76 Million
Q2 2019 Aug 14, 2019	BUY	$80.35 - $93.9 $22.6 Million - $26.4 Million	281,636 Added 59167.23%	282,112 $24.2 Million
Q1 2019 May 14, 2019	SELL	$84.2 - $98.62 $2.62 Million - $3.07 Million	-31,097 Reduced 98.49%	476 $42,000
Q4 2018 Feb 14, 2019	BUY	$80.14 - $106.07 $1.75 Million - $2.31 Million	21,784 Added 222.54%	31,573 $2.69 Million
Q3 2018 Nov 14, 2018	BUY	$93.92 - $105.72 $592,541 - $666,987	6,309 Added 181.29%	9,789 $949,000
Q2 2018 Aug 14, 2018	SELL	$76.01 - $99.03 $359,451 - $468,312	-4,729 Reduced 57.61%	3,480 $328,000
Q1 2018 May 15, 2018	BUY	$77.67 - $92.63 $218,408 - $260,475	2,812 Added 52.1%	8,209 $666,000
Q4 2017 Feb 14, 2018	BUY	$80.76 - $95.13 $435,861 - $513,416	5,397	5,397 $481,000

Others Institutions Holding BMRN

# of Institutions

637

Shares Held

177M

Call Options Held

2.01M

Put Options Held

1.28M

Black Rock Inc. New York, NY

22.7M
Shares

$1.52 Billion
0.04% of portfolio
Vanguard Group Inc Valley Forge, PA

19.3M
Shares

$1.28 Billion
0.02% of portfolio
Primecap Management CO Pasadena, CA

18.9M
Shares

$1.26 Billion
0.99% of portfolio
Dodge & Cox San Francisco, CA

13.9M
Shares

$926 Million
0.59% of portfolio
Capital Research Global Investors Los Angeles, CA

10.5M
Shares

$699 Million
0.16% of portfolio

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.4B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Account